Heron Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Heron Therapeutics

03/05/2024 12:41

* Heron Therapeutics Inc  HRTX.OQ   HRTX.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 7 for
the period ending March 31 2024
    * The San Diego California-based  company is expected to
report a
11.3% increase in revenue to $32.975 million from $29.62 million
a year ago, according to the mean estimate from 4 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Heron Therapeutics Inc
is for
a loss of 9 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Heron
Therapeutics Inc is $6.50​, above​ its last closing price
of $2.55. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.16       -0.16      -0.07     Beat    57.2
 Sep. 30 2023  -0.29       -0.29      -0.17     Beat    41.9
 Jun. 30 2023  -0.23       -0.23      -0.35     Missed  -50​
 Mar. 31 2023  -0.21       -0.20      -0.27     Missed  -33
 ​​Dec.        -0.30       -0.28      -0.17     Beat    40.4
 31 2022                                                
 Sep. 30 2022  -0.38       -0.38      -0.38     Met     -1.1​
 Jun. 30 2022  -0.53       -0.50      -0.55     Missed  -8.9
 Mar. 31 2022  -0.49       -0.48      -0.63     Missed  -32.4
 This summary was machine generated May 3 at 11:41 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)